Chemicon International, the research division of Serologicals, has entered into an exclusive licensing agreement with Myriad Genetics for the research use of several of tumor suppressor and breast cancer susceptibility proteins and antibodies.

The patented targets licensed to Chemicon are used primarily in the study of human malignancies. Two are cancer susceptibility genes expressed in a high percentage of breast and ovarian cancers and cell lines, while the others act as tumor suppressor genes and are frequently deleted or mutated in a wide variety of human tumors.

Chemicon says it anticipates that products and assays resulting from this agreement will be used widely by researchers in academia and industry to further characterize the important role that these proteins play in various forms of human cancers.

Under the terms of the agreement, Chemicon obtains intellectual property in the research field of use. The agreement excludes commercial therapeutic and diagnostic rights and rights to fields of use that Chemicon does not currently serve.

“Our agreement with Myriad Genetics strengthens our commitment to provide the research community with enabling technologies, as well as the finest products needed to facilitate advances in the study of functional genomics and proteomics,” said Chemicon President Jeffrey Linton. “This collaboration lays the foundation for a strong and mutually beneficial relationship providing cancer researchers and biotechnology scientists with the innovative research tools needed to make breakthrough discoveries.”

Chemicon: www.chemicon.com